Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GASPAR: Perioperative spartalizumab plus FLOT in resectable gastric cancer
2020-004497-21Phase 2Active
- Sponsor
- Centre François Baclesse
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Centre François Baclesse. Primary endpoint: Pathologic complete response (pCR) in primary tumour. Started Dec 2020; status: active.
02
Drugs
spartalizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2020-004497-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004497-21.